Indeed, a vaccine against meningococcus B, the first deriving from reverse vaccinology, has recently been licensed ( Serruto et al., 2012 O’Ryan et al., 2014). The process was named “reverse vaccinology” to underline that vaccine design was possible starting from sequence information without the need to grow pathogens ( Rappuoli, 2000). Two decades ago, genome sequencing revolutionized this process, allowing for the discovery of novel vaccine antigens starting directly from genomic information. Traditionally, vaccines have been developed empirically by isolating, inactivating, and injecting the microorganisms (or portions of them) that cause disease ( Table 1 Rappuoli, 2014).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |